About SUNSHINE PHARMA Company

We are a comprehensive pharmaceutical company driven by independent R&D, rooted in China and oriented toward the global market. With integrated capabilities spanning R&D, manufacturing, and sales, we focus on three key therapeutic areas: infectious diseases, chronic diseases, and oncology. The Company has established a diversified, robust, and commercially promising pipeline of innovative drugs in development, along with end-to-end, independently developed R&D capabilities and a full-spectrum R&D platform and technologies covering the entire lifecycle of both small-molecule and biologic drug development. Our R&D team comprises nearly 1,000 professionals, including scientists with extensive experience at multinational pharmaceutical companies and highly seasoned pharmaceutical talent. The Company has been recognized with numerous national-level designations and provincial awards, such as National Key Laboratory, National Intellectual Property Demonstration Enterprise, Postdoctoral Research Station, and First Prize for Scientific and Technological Progress of Guangdong Province. Founded on December 29, 2003, in Dongguan City, Guangdong Province, China, the Company has more than two decades of operating history as of the date of this report. Its pharmaceutical sales performance and R&D capabilities place it among the leaders in China's pharmaceutical industry. In 2005, the Company established a research institute dedicated to developing its own R&D platform. From 2006 to 2010, it embarked on independent small-molecule drug discovery. Between 2011 and 2015, the Company achieved a significant milestone in globalization when its azithromycin tablets were approved in Europe. From 2016 to 2020, the Company's Class 1 innovative drug, Dongweien (emtricitabine phosphate), received marketing approval from the China National Medical Products Administration ("NMPA"). In November 2021, the Company acquired 51.41% of the total share capital of Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd. ("Dongyangguang Changjiang") from Guangdong Dongyangguang Technology Holdings Co., Ltd. On June 21, 2023, the Company was restructured into a joint-stock company. In February and March 2025, the Group's Dongweizhuo (nafamostat mesylate capsules) and Dongyinghe (elbasvir/grazoprevir tablets), used in combination for the treatment of genotype 1, 2, 3, and 6 hepatitis C virus infections in adults who are treatment-naïve or have previously received interferon-based therapy, were respectively approved for marketing in China. On August 7, 2025, the Company was officially listed on the Main Board of the Hong Kong Stock Exchange under the stock code "06887.HK." Since its inception, the Company has adhered to the pharmaceutical philosophy of "serving the Chinese people with higher standards," maintaining a strong industrial foundation and leading competitive advantages in both drug manufacturing and marketing. As of December 31, 2025, the Company operates a nationwide product distribution network in China, supported by 1,892 professional sales personnel. Our sales network covers more than 2,600 tertiary hospitals, over 9,600 secondary hospitals, and more than 89,000 primary hospitals, as well as numerous large-scale national and regional pharmacy chains and other healthcare institutions, enabling us to achieve maximum market coverage across the country. In addition, our overseas sales network spans eight countries and regions, and we maintain long-term sales partnerships with globally renowned pharmaceutical companies, laying a solid foundation for the continued expansion of our international business. One of the Group's core products—Kewei (oseltamivir phosphate)—is a first-line antiviral medication for influenza in China, with its granule formulation being an exclusive patented product of the Company. Oseltamivir phosphate is listed as an essential medicine on the World Health Organization's Model List of Essential Medicines and is recommended by the U.S. Centers for Disease Control and Prevention as one of the key antiviral agents for treating influenza and avian influenza viruses, including H5N1. In China, oseltamivir phosphate was included in the National Essential Medicines List (2018 Edition) in 2018 and is endorsed as a first-line antiviral agent for influenza treatment in multiple clinical practice guidelines, such as the Expert Consensus on Antiviral Treatment of Adult Influenza, the Expert Consensus on Emergency Management of Adult Influenza (2022 Edition), and the Expert Consensus on Diagnosis and Treatment of Pediatric Influenza (2020 Edition). In 2024, the Group's oseltamivir phosphate products were again included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2024 Edition) issued by the Ministry of Human Resources and Social Security of China. In 2025, the Group's Kewei granule patent, "Oseltamivir Phosphate Granules and Their Preparation Method," was awarded the 25th China Patent Gold Award. The Company's full-lifecycle drug development platform and independent R&D capabilities are leading in China, with a focus on innovative medicines while also encompassing improved new drugs, generic drugs, and biosimilars. Through diversified molecular design and a comprehensive technological platform, we have built a diverse, robust pipeline with broad and deep indications coverage. The Group currently has more than 150 approved drugs, four innovative drugs already on the market, and 50 Class 1 innovative drugs in development, over ten of which are in Phase II or Phase III clinical trials. This diversified and powerful drug pipeline not only secures our position in China's pharmaceutical R&D landscape but also supports our sustainable development and growth trajectory. In addition, the Group has established strategic partnerships with numerous well-known enterprises: We have signed letters of intent with the Wuhan Institute of Virology of the Chinese Academy of Sciences and the National Engineering Research Center for Emergency Prevention and Control Drugs, under which the parties will jointly establish a national military-civilian fusion collaborative industrialization platform for emergency prevention and control drugs and a national antiviral drug center; we have entered into an exclusive cooperation agreement with Guoren Health Pharmaceutical (Beijing) Co., Ltd. ("Guoren Health") to promote and sell the original imported pediatric faropenem sodium granules (Firum) in China, obtaining exclusive sales rights for this product domestically and further enriching our pediatric product line; we have concluded an exclusive licensing and commercialization agreement with Apollo Therapeutics Group Limited regarding the investigational product HEC88473, aimed at accelerating the development and commercialization of HEC88473 in international markets, complementing our efforts in the Chinese market; we have signed an exclusive commercialization cooperation agreement ("Clofotinib Agreement") with Shenyang Sansheng Pharmaceutical Co., Ltd., whereby Sansheng Pharmaceutical's expertise and capabilities in the commercialization and marketing of hematological drugs will significantly bolster the commercialization of Clofotinib; we have entered into a comprehensive cooperation agreement with Huawei Cloud Computing Technologies Co., Ltd. to jointly explore collaboration in the field of AI large models for the pharmaceutical industry and co-create industry-leading AI large models; we have signed a comprehensive strategic cooperation agreement with Beijing DeepMotion Technology Co., Ltd. to deeply investigate how artificial intelligence can effectively drive the practical application of drug R&D and jointly promote new trends in the biopharmaceutical industry; we have partnered with Beijing Sanwei Tiandi Technology Co., Ltd. ("Sanwei Tiandi") to co-establish the "AI + Pharmacological Digital Intelligence R&D Joint Laboratory," integrating the strengths of both parties in pharmaceutical R&D and artificial intelligence to build a next-generation intelligent drug R&D system; we have formally signed a strategic cooperation framework agreement with Dongguan Advanced Industrial Software Innovation Co., Ltd., focusing on core dimensions such as data governance system construction, algorithm model iteration and optimization, and intelligent platform development, with the aim of creating an industrial-grade AI pharmaceutical solution that integrates data, models, and applications; we have reached a strategic cooperation with Beijing Zhongda Weixin Technology Co., Ltd. ("Weixin Computing"), under which the two parties will engage in deep collaboration on the construction and refinement of Dongyangguang Pharma's HEC drug intelligent discovery platform, jointly promoting the digital transformation of the entire innovative drug R&D process, thereby breaking through traditional R&D efficiency bottlenecks and shortening the preclinical development cycle of innovative drugs; and we have entered into a strategic cooperation agreement with Shenzhen Jingtai Technology Co., Ltd. ("Shenzhen Jingtai"), under which the two parties plan to establish a joint venture to build an AI-driven drug R&D platform, leveraging the Group's rich pharmaceutical R&D heritage and Jingtai Technology's intelligent engine to usher in a new era of pharmaceutical R&D. The Company believes that these strategic partnerships will deliver ideal growth prospects for our business. The Company consistently pursues a development strategy centered on specialization, branding, and differentiation, committed to building a highly professional marketing team, implementing steady and innovative market operations, and strategically integrating resources. Through these efforts, we aim to establish the unique brand identity and core competitiveness of "Dongyangguang Pharma" within the industry, creating greater value for pharmaceutical consumers and partners alike. Looking ahead, the Company will further enrich its product portfolio, expand into new markets, and elevate the international production standards and quality of its products. We will continue to broaden the scope of our marketing and sales efforts to drive further growth in our business and profitability, delivering greater economic returns and benefits to our investors.